Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

NCT06427668 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: SPG302
DRUG: Placebo

Sponsor

Spinogenix